{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:24:00Z","timestamp":1790796240545,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00836-0","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:01:51Z","timestamp":1701331311000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-\u03b1 antibody drugs for Crohn\u2019s disease: three case reports and literature review"],"prefix":"10.1007","volume":"13","author":[{"given":"Akihiro","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Haruhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"issue":"2","key":"836_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.04660513","volume":"9","author":"JM Ambruzs","year":"2014","unstructured":"Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265\u201370.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"836_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000511555","volume":"145","author":"R Nurmi","year":"2021","unstructured":"Nurmi R, Pohjonen J, Metso M, et al. Prevalence of inflammatory bowel disease and celiac disease in patients with IgA nephropathy over time. Nephron. 2021;145(1):78\u201384.","journal-title":"Nephron"},{"issue":"2","key":"836_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1681\/ASN.2020060848","volume":"32","author":"J Rehnberg","year":"2021","unstructured":"Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study. J Am Soc Nephrol. 2021;32(2):411\u201323.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"836_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12328-009-0112-x","volume":"2","author":"Y Ueno","year":"2009","unstructured":"Ueno Y, Tanaka S, Onitake T, et al. Infliximab treatment for Crohn\u2019s disease in a patient with IgA nephropathy. Clin J Gastroenterol. 2009;2(6):380\u20133.","journal-title":"Clin J Gastroenterol"},{"issue":"3","key":"836_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226442","volume":"12","author":"AKB Singh","year":"2019","unstructured":"Singh AKB, Jeyaruban AS, Wilson GJ, Ranganathan D. Adalimumab-induced IgA nephropathy. BMJ Case Rep. 2019;12(3): e226442.","journal-title":"BMJ Case Rep"},{"issue":"9","key":"836_CR6","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000462","volume":"7","author":"T Strobel","year":"2020","unstructured":"Strobel T, Ahmed W, De la Sancha C, Bohm M, Fischer M. IgA nephropathy in the setting of anti-TNF-\u03b1 therapy for inflammatory bowel disease. ACG Case Rep J. 2020;7(9): e00462.","journal-title":"ACG Case Rep J"},{"issue":"2","key":"836_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000515585","volume":"11","author":"T Mertelj","year":"2021","unstructured":"Mertelj T, Smrekar N, Kojc N, Lindi\u010d J, Kova\u010d D. IgA nephropathy in a patient treated with adalimumab. Case Rep Nephrol Dial. 2021;11(2):233\u201340.","journal-title":"Case Rep Nephrol Dial"},{"issue":"3","key":"836_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ndt\/gfaa378","volume":"37","author":"N Joher","year":"2022","unstructured":"Joher N, Gosset C, Guerrot D, et al. Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transplant. 2022;37(3):531\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"9156","key":"836_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi G, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883\u20137.","journal-title":"Lancet"},{"issue":"7","key":"836_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12(7):703\u20138.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"836_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun Rev. 2010;9(3):188\u201393.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"836_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-De-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56\u201364.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"836_CR13","first-page":"440","volume":"28","author":"E Marocchi","year":"2010","unstructured":"Marocchi E, Spadaro A, Giannakakis K, Priori R, Valesini G. Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis. Clin Exp Rheumatol. 2010;28(3):440.","journal-title":"Clin Exp Rheumatol"},{"key":"836_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/812781","author":"SS Wei","year":"2013","unstructured":"Wei SS, Sinniah R. Adalimumab (TNF\u03b1 inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. Case Rep Nephrol. 2013. https:\/\/doi.org\/10.1155\/2013\/812781.","journal-title":"Case Rep Nephrol"},{"issue":"3","key":"836_CR15","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.12622","volume":"54","author":"N Kluger","year":"2015","unstructured":"Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G. Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol. 2015;54(3):e79\u201380.","journal-title":"Int J Dermatol"},{"issue":"11","key":"836_CR16","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1093\/ndt\/gfp314","volume":"24","author":"A Jacquet","year":"2009","unstructured":"Jacquet A, Francois H, Frangie C, et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant. 2009;24(11):3540\u20132.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"836_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10067-006-0422-z","volume":"26","author":"GT Sakellariou","year":"2007","unstructured":"Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol. 2007;26(7):1132\u20133.","journal-title":"Clin Rheumatol"},{"key":"836_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9480860","author":"V Premu\u017ei\u0107","year":"2020","unstructured":"Premu\u017ei\u0107 V, Padjen I, Cerovec M, \u0106ori\u0107 M, Jelakovi\u0107 B, Ani\u0107 B. The association of TNF-alpha inhibitors and development of IgA nephropathy in patients with rheumatoid arthritis and diabetes. Case Rep Nephrol. 2020. https:\/\/doi.org\/10.1155\/2020\/9480860.","journal-title":"Case Rep Nephrol"},{"issue":"1","key":"836_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-020-02015-0","volume":"21","author":"Y Segawa","year":"2020","unstructured":"Segawa Y, Ishida R, Kanehisa F, et al. IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis. BMC Nephrol. 2020;21(1):1\u20136.","journal-title":"BMC Nephrol"},{"issue":"4","key":"836_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5217\/ir.2020.00067","volume":"19","author":"R Hayashi","year":"2021","unstructured":"Hayashi R, Ueno Y, Tanaka S, et al. Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy. Intest Res. 2021;19(4):430\u20137.","journal-title":"Intest Res"},{"issue":"1","key":"836_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13730-020-00508-3","volume":"10","author":"M Lee","year":"2021","unstructured":"Lee M, Suzuki H, Kato R, et al. Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. CEN Case Rep. 2021;10(1):17\u201322.","journal-title":"CEN Case Rep"},{"issue":"5","key":"836_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","volume":"61","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Abitbol V, El Karoui K, et al. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-\u03b1 blockers. Rheumatology (Oxford). 2022;61(5):1957\u201365.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"836_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","volume":"87","author":"O Sokumbi","year":"2012","unstructured":"Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors. Mayo Clin Proc. 2012;87(8):739\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"836_CR24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ajg.2016.54","volume":"111","author":"JP Gisbert","year":"2016","unstructured":"Gisbert JP, Mar\u00edn AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111(5):632\u201347.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"836_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.5009\/gnl20233","volume":"15","author":"JH Song","year":"2021","unstructured":"Song JH, Kang EA, Park SK, et al. Long-term outcomes after the discontinuation of anti-tumor necrosis factor-\u03b1 therapy in patients with inflammatory bowel disease under clinical remission: a Korean association for the study of intestinal disease multicenter study. Gut Liver. 2021;15(5):752\u201362.","journal-title":"Gut Liver"},{"issue":"3","key":"836_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10157-018-1665-0","volume":"23","author":"J Ruszkowski","year":"2019","unstructured":"Ruszkowski J, Lisowska KA, Pindel M, Heleniak Z, D\u0119bska-\u015alizie\u0144 A, Witkowski JM. T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target. Clin Exp Nephrol. 2019;23(3):291\u2013303.","journal-title":"Clin Exp Nephrol"},{"key":"836_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104835","volume":"158","author":"M Leppkes","year":"2020","unstructured":"Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases - update 2020. Pharmacol Res. 2020;158: 104835.","journal-title":"Pharmacol Res"},{"issue":"3","key":"836_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0272-6386(03)00801-1","volume":"42","author":"RJ Johnson","year":"2003","unstructured":"Johnson RJ, Hurtado A, Merszei J, Rodriguez-Iturbe B, Feng L. Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am J Kidney Dis. 2003;42(3):575\u201381.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"836_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4772","volume":"2","author":"K Hirano","year":"2019","unstructured":"Hirano K, Matsuzaki K, Yasuda T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin a nephropathy. JAMA Netw Open. 2019;2(5): e194772.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"836_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/0886022X.2013.862809","volume":"36","author":"L He","year":"2014","unstructured":"He L, Peng Y, Liu H, et al. Th1\/Th2 polarization in tonsillar lymphocyte form patients with IgA nephropathy. Ren Fail. 2014;36(3):407\u201312.","journal-title":"Ren Fail"},{"issue":"3","key":"836_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology. 2019;157(3):647\u201359.","journal-title":"Gastroenterology"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00836-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:14:02Z","timestamp":1722507242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00836-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00836-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not conduct any tests on any human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}